Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma

Journal of the Pancreas

Volumn 12, Issue 4, 2011, Pages 351-354

  Makrilia, Nektaria ^a   Syrigos, Kostas N ^a   Saif, Muhammad W ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Capecitabine; Lapatinib; Pancreatic neoplasms; S 1; Treatment failure

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CISPLATIN; DOCETAXEL; ERIBULIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; SUNITINIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHICAGO; CONGRESSES AS TOPIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 79960205464     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 20-22, 2011. JOP. J Pancreas (Online) 2011; 12:96-100.
3. Makrilia N, Syrigos KN, Saif MW. Treatment for refractory pancreatic cancer. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 20-22, 2011. JOP. J Pancreas (Online) 2011; 12:110-3.
4. Oettle H, Pelzer U., Stieler J., Hilbig A., Roll L., Schwaner I., et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in secondline therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23(Suppl. 16):4031.
5. Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Gorner M., et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(Suppl.):4508.
6. Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; April 1:[Epub ahead of print].
7. Saif MW, Syrigos K, Penney R, Kaley K. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 2010; 30:2905-9.
8. Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, et al A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2011; April 28:-[Epub ahead of print].
9. Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, et al. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine-and 5-fluorouracilrefractory pancreatic cancer. Invest New Drugs 2010; 28:343-9.
10. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabinerefractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-63.
11. Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefevre L, Raymond E, et al. FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients. 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29(Suppl. 4):272.
12. Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, et al. A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. 2011 Gastrointestinal Cancers Symposium. J Clin Oncol 2011; 29(Suppl. 4):237.
13. Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-7.
14. Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? JOP. J Pancreas (Online) 2007; 8:799-805.
15. Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, et al. Bevacizumab plus gemcitabine and oxaliplatin as firstline therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011; April 9:-[Epub ahead of print].
16. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008; 19:340-7.
17. Pino MS, Milella M, Gelibter A, Sperduti I, De MS, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76:254-61.
18. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67:361-8.
19. Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 2010; 40:567-72.
20. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63:313-9.
21. Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O. Phase II study of S-1 in patients with gemcitabineresistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67:249-54.
22. Shitara K, Komatsu Y, Yuki S, Munakata M, Muto O, Shimaya S, Sakata Y. Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer. Oncology 2008; 75:67-70.
23. Togawa A, Yoshitomi H, Ito H, Kimura F, Shimizu H, Ohtsuka M, et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol 2007; 12:268-73.
24. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010; 15:1310-9.
25. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27:193-8.
26. Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, et al. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol 2011; 34:70-5.
27. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010; 66:1051-7.
28. Komoto M, Nakata B, Nishii T, Kawajiri H, Shinto O, Amano R, et al. In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. Cancer Sci 2010; 101:468-73.
29. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, et al. Capecitabine plus erlotinib in gemcitabinerefractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787-92.
30. Ishido K, Toyoki Y, Kudo D, Nrumi S, Hakamada K. Impact of S-1 as the second-line chemotherapy for patients with relapsing pancreatic cancer. J Clin Oncol 2011; 29(Suppl.):e14588.
31. He RR, Hwang JJ, Marshall JJ, Pishvaian M, Slack R, Weiner M, Wellstein A. A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer. J Clin Oncol 2011; 29(Suppl.):e14542.
32. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy. Clin Oncol (R Coll Radiol) 2011; March 5:-[Epub ahead of print].
33. Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 2008; 31:140-4.
34. McDermott RS, Calvvert P, Parker M, Webb G, Moulton B, McCaffrey J, Irish Clinical Oncology Research Group. A phase II study of lapatinib and capecitabine in first-line treatment of metastatic pancreatic cancer (ICORG 08-39). J Clin Oncol 2011; 29(Suppl. 4):315.
35. Saif MW. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. JOP. J Pancreas (Online) 2007; 8:166-76.